DGAP-News: BioCrea GmbH: BioCrea's Anti Depression Program

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: BioCrea GmbH: BioCrea's Anti Depression Program Voted Top Neuroscience Project to Watch

DGAP-News: BioCrea GmbH / Key word(s): Conference BioCrea GmbH: BioCrea's Anti Depression Program Voted Top Neuroscience Project to Watch 18.11.2014 / 09:30 --------------------------------------------------------------------- BioCrea's Anti Depression Program Voted "Top Neuroscience Project to Watch" BioCrea invited to present NMDA NR2B NAM program at the Therapeutic Area Partnerships meeting on November 19-21, 2014 in Boston Radebeul, Germany, November 18, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that the Company's NMDA NR2B NAM program has been chosen as one of the "Top Neuroscience Projects to Watch" by Informa's IN VIVO, Start-up and The Pink Sheet. The NMDA NR2B small molecule program is currently being developed to treat Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD). BioCrea has been invited to present the project at the Therapeutic Area Partnerships (TAP) meeting, which takes place on November 19-21, 2014 in Boston, USA: Session: Track 1: Neuroscience Presentation: Dr. Tom Kronbach, CEO of BioCrea Title: "On Target with Rapid Acting Antidepressants" Date and Time: Thursday, November 20, 2014, 11:40 AM EST Location: The Hyatt Regency Boston, Room: Duxbury "Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider to be the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners and acquirers." The "Top Neuroscience Projects to Watch" have been chosen by independent industry experts. BioCrea met the selection criteria, which included: an unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. "We are complimented to be selected as one of the 'Top Neuroscience Projects to Watch' by these independent Informa experts", said Dr. Tom Kronbach, CEO of BioCrea GmbH. "We very much appreciate this opportunity to discuss our NMDA NR2B NAM program at the TAP meeting, which is one of the key neuroscience events." About BioCrea BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychiatric disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). For more information, please visit www.biocrea.com. About the Therapeutic Area Partnerships (TAP) A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas). Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. Contact Dr. Tom Kronbach CEO, BioCrea GmbH Tel.: +49 351 / 4043 3332 Fax: +49 351 / 4043 3216 tom.kronbach@biocrea.com --------------------------------------------------------------------- 18.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 297721 18.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 66

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 33

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 64

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 25

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 56

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

KLA Corporation Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 118

KLA Corporation Declares Cash Dividend for Investors The KLA Corporation (NASDAQ: KLAC), renowned for its innovation within the electronics industry, has taken a significant step to reward its shareholders. The Board of Directors recently announced a quarterly cash dividend of $1.90 per share. This decision reflects KLA's commitment to delivering value to its investors...

Continue Reading
Peptone Market Growth Projected to Reach $240.5 Million

Updated Category News Views 170

Overview of the Peptone Market The peptone market is on an impressive growth trajectory, expected to reach an estimated value of $240.5 million by 2035. This significant growth is attributed to a compound annual growth rate (CAGR) of 4.2% from 2024 to 2035. The driving forces behind this trend include rising demand in biopharmaceutical production, the application of...

Continue Reading
Roch Dog Introduces Innovative AI Certification for Hotels

Updated Category News Views 310

Revolutionizing Pet-Friendly Travel with AI Roch Dog, an NVIDIA Inception startup, has disrupted the hotel industry by launching the first AI certification engine focused on pet-friendly hotels. This innovative platform streamlines the processes of assessment, certification, ranking, and review of hotels based on their pet-friendly offerings. With a commitment to...

Continue Reading
Major Holdings Update from Wellington Management Group LLP

Updated Category News Views 198

Understanding Major Holdings Notifications In the world of finance and investments, major holdings notifications play a vital role in maintaining transparency and trust among investors and stakeholders. This process helps companies keep everyone informed about significant changes in ownership, which can impact decision-making and share prices. Today, we will delve into...

Continue Reading
German Housing Market Shows Signs of Recovery Amid Declines

Updated Category News Views 148

Recent Trends in the German Housing Market In the second quarter, Germany saw a significant drop in residential property prices, averaging a decrease of 2.6% compared to last year. However, a new report from the federal statistics office reveals some encouraging signs that suggest the market may be stabilizing. Quarterly Growth Despite Yearly Declines While the annual...

Continue Reading